December 1, 2014

homepage

April 27, 2016

X-Chem Announces Achievement of Milestone in Alexion Collaboration

WALTHAM, Mass. – April 27 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX™) drug discovery platform for the identification of first-in-class small molecule therapeutics, today announced that it has achieved a milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a payment to […]

Continue Reading
March 30, 2016

X-Chem Announces License with Janssen for Protein:Protein Inhibitor Program in Inflammatory Disease

WALTHAM, Mass. – March 30, 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor […]

Continue Reading
January 6, 2016

X-Chem Collaborates with Sanofi on the Discovery of Lead Molecules against Multiple Challenging Targets

WALTHAM, Mass. – January 6 , 2015 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, announced a multi-target collaboration with Sanofi. The collaboration is focused on the potential development of several programs for treatments in therapeutic areas such as oncology, rare […]

Continue Reading